Amgen Shares Surge 9.7% on Repatha Trial Success Puerto Rico Expansion

Amgen's stock has experienced a significant rise, with a recent surge of around 6% attributed to positive clinical trial results for its cardiovascular drug Repatha and a $650 million expansion of its manufacturing facility in Juncos, Puerto Rico, which is expected to create nearly 750 jobs. This expansion aligns with Amgen's strategic focus on domestic production and supply chain resilience amid changing regulatory and trade conditions. The successful Phase 3 VESALIUS-CV trial for Repatha bolsters Amgen's growth outlook in the primary prevention cardiovascular market, contributing to investor confidence and a strong earnings report. Despite this optimism, persistent drug pricing pressures, including calls for lower prices from President Trump, pose ongoing risks to Amgen's earnings momentum. The stock's recent strong performance includes multiple consecutive days of gains and stands out as a leading performer in major indices, reflecting investor enthusiasm about its long-term growth prospects. However, some market uncertainty remains regarding whether these growth catalysts will sustain outsized returns over time.